ES2129615T3 - Uso de dimetilbenzofuranos y dimetilbenzopiranos como antagonistas 5-ht3. - Google Patents

Uso de dimetilbenzofuranos y dimetilbenzopiranos como antagonistas 5-ht3.

Info

Publication number
ES2129615T3
ES2129615T3 ES94900151T ES94900151T ES2129615T3 ES 2129615 T3 ES2129615 T3 ES 2129615T3 ES 94900151 T ES94900151 T ES 94900151T ES 94900151 T ES94900151 T ES 94900151T ES 2129615 T3 ES2129615 T3 ES 2129615T3
Authority
ES
Spain
Prior art keywords
represents hydrogen
formula
new compounds
dimethylbenzopyrans
dimethylbenzofurans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94900151T
Other languages
English (en)
Spanish (es)
Inventor
Daele Georges Henri Paul Van
Jean-Paul Rene Marie A Bosmans
Laerhoven Willy Joannes Ca Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2129615T3 publication Critical patent/ES2129615T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Dental Preparations (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES94900151T 1992-11-20 1993-11-15 Uso de dimetilbenzofuranos y dimetilbenzopiranos como antagonistas 5-ht3. Expired - Lifetime ES2129615T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97901392A 1992-11-20 1992-11-20

Publications (1)

Publication Number Publication Date
ES2129615T3 true ES2129615T3 (es) 1999-06-16

Family

ID=25526607

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94900151T Expired - Lifetime ES2129615T3 (es) 1992-11-20 1993-11-15 Uso de dimetilbenzofuranos y dimetilbenzopiranos como antagonistas 5-ht3.

Country Status (31)

Country Link
US (2) US5674868A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0669919B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2830952B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR0166661B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE176232T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU680640B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG62489B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9307477A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2149044C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ287262B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69323322T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0669919T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2129615T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI952458A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3029831T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUT72740A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL119273A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LV (1) LV10956B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9307257A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO307690B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ257854A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
OA (1) OA10158A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL176051B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO115160B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2116072C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG47488A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK282378B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW294595B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA49792C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1994012494A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA938676B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
KR100529512B1 (ko) 1997-04-18 2005-11-22 얀센 파마슈티카 엔.브이. 장 세척 촉진을 위한 5ht3 길항제의 용도
EP1000029B1 (en) * 1997-07-11 2003-10-01 Janssen Pharmaceutica N.V. (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders
US6239122B1 (en) * 2000-01-05 2001-05-29 Joy Ann Steele Method of treatment of nausea, vomiting, and other disorders using estrogens
WO2004111014A1 (en) * 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
CN1882549B (zh) 2003-11-20 2011-02-23 詹森药业有限公司 用作聚(adp-核糖)聚合酶抑制剂的7-苯基烷基取代的2-喹啉酮和2-喹喔啉酮
MXPA06005687A (es) 2003-11-20 2006-08-17 Janssen Pharmaceutica Nv 2-quinolinonas y 2-quinoxalinonas sustituidas con 6-alquenilo y 6-fenilalquilo como inhibidores de la poli(adenosin fosfato-ribosa)polimerasa.
ES2415771T3 (es) 2004-06-30 2013-07-26 Janssen Pharmaceutica N.V. Derivados de quinazolina como inhibidores de PARP
CA2569824C (en) 2004-06-30 2013-03-19 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
BRPI0512790A (pt) 2004-06-30 2008-04-08 Janssen Pharmaceutica Nv derivados de 2-alquil quinazolinona substituìdos como inibidores de parp
HRP20120346T1 (hr) 2007-03-08 2012-05-31 Janssen Pharmaceutica N.V. Derivati kinolinona kao parp i tank inhibitori
ES2448870T3 (es) 2007-10-26 2014-03-17 Janssen Pharmaceutica, N.V. Derivados de quinolina como inhibidores de PARP
EP2271626B1 (en) 2008-03-27 2014-11-26 Janssen Pharmaceutica, N.V. Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors
CA2716088C (en) 2008-03-27 2017-03-07 Eddy Jean Edgard Freyne Quinazolinone derivatives as tubulin polymerization inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZW12187A1 (en) * 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US4914207A (en) * 1989-05-09 1990-04-03 Pfizer Inc. Arylthiazolylimidazoles
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives

Also Published As

Publication number Publication date
EP0669919B1 (en) 1999-01-27
CA2149044C (en) 2007-04-03
NO995762D0 (no) 1999-11-24
SK282378B6 (sk) 2002-01-07
GR3029831T3 (en) 1999-06-30
IL119273A (en) 2000-07-16
JPH08505840A (ja) 1996-06-25
US5863923A (en) 1999-01-26
KR0166661B1 (ko) 1999-01-15
HUT72740A (en) 1996-05-28
UA49792C2 (uk) 2002-10-15
RU95113434A (ru) 1997-03-10
EP0669919A1 (en) 1995-09-06
DE69323322T2 (de) 1999-09-09
PL309045A1 (en) 1995-09-18
PL176051B1 (pl) 1999-03-31
TW294595B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-01-01
SK67595A3 (en) 1995-11-08
ATE176232T1 (de) 1999-02-15
LV10956A (lv) 1995-12-20
US5674868A (en) 1997-10-07
FI952458A0 (fi) 1995-05-19
MX9307257A (es) 1994-05-31
NO951980L (no) 1995-05-19
BG99593A (en) 1995-12-29
SG47488A1 (en) 1998-04-17
BR9307477A (pt) 1999-06-29
LV10956B (en) 1996-10-20
HU211546A9 (en) 1995-12-28
NO951980D0 (no) 1995-05-19
IL107654A0 (en) 1994-02-27
AU5465994A (en) 1994-06-22
NZ257854A (en) 1997-04-24
IL107654A (en) 1998-01-04
NO308530B1 (no) 2000-09-25
FI952458L (fi) 1995-05-19
WO1994012494A1 (en) 1994-06-09
NO995762L (no) 1995-05-19
ZA938676B (en) 1995-05-19
CA2149044A1 (en) 1994-06-09
BG62489B1 (bg) 1999-12-30
HU9501476D0 (en) 1995-07-28
FI952458A7 (fi) 1995-05-19
JP2830952B2 (ja) 1998-12-02
OA10158A (en) 1996-12-18
DE69323322D1 (de) 1999-03-11
CZ287262B6 (en) 2000-10-11
RO115160B1 (ro) 1999-11-30
NO307690B1 (no) 2000-05-15
RU2116072C1 (ru) 1998-07-27
DK0669919T3 (da) 1999-09-13
IL119273A0 (en) 1996-12-05
AU680640B2 (en) 1997-08-07
CZ125895A3 (en) 1995-10-18

Similar Documents

Publication Publication Date Title
ES2129615T3 (es) Uso de dimetilbenzofuranos y dimetilbenzopiranos como antagonistas 5-ht3.
MX9203239A (es) Derivados de 1-(dihidroxifenil)-2-amino-etanol y composiciones farmaceuticas que los contienen.
ES8601829A1 (es) Un procedimiento para la preparacion de derivados de eteres alquilfenilicos.
AR245705A1 (es) Un proceso para preparar leucotrienos-antagonistas y sus sales.
ES2164720T3 (es) Derivados de piperidina como agentes anticolinergicos.
CO4920223A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona 8- sustituidos
ES2164920T3 (es) Nuevos derivados heterociclicos y uso medicinal de los mismos.
ES8504690A1 (es) Un procedimiento para preparar una n-(4-(3-aminopropil)-aminobutil)-2-(acido w-guanidino-graso-amido)-2-alcoxietanamida
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
SE8600413D0 (sv) Nytt lekemedel och sett att framstella detsamma
DK489180A (da) Fremgangsmaade til fremstilling af sekundaere aminer
FI812804L (fi) 2-(1,4-bensodioxan-2-ylalkyl)-imidazoler anvaendbara som antidepressiva laekemedel
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
ES8304122A1 (es) "procedimiento para la preparacion de derivados triptaminicos sustituidos de tieniloxipropanolaminas, racemicos y opticamente activos".
DK0871626T3 (da) Triazoloner som apolipoprotein-B syntheseinhibitorer
AR003932A1 (es) Oxidiazoles procineticos, su uso como medicamento, una composicion farmaceutica que los contiene, un procedimiento para preparar dicha composicion
ES450897A1 (es) Procedimiento para la preparacion de n-(r-tetrahidrofurfu- ril)-noroximorfona y n-(s-tetrahidrofurfuril)-noroximorfona.
AR002264A1 (es) 6-[triazolil[3(trifluormetil)fenil]metil]-2-quinolinonas y quinolintionas, un procedimiento para su preparacion, una composicion que las comprende, unprocedimiento para su preparacion, el uso de las mismas para la preparacion de un medicamento y un intermediario.
AR018675A1 (es) Derivados de 3-(2-oxo-[1,3¿i¿]bipirrolidinil-3-ilidenometil)-cefem, una composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento.
SE8203057L (sv) Forbettrat brensle med gasolja som huvudbestandsdel, innefattande vatten och en alkohol
IT1210926B (it) Derivati della 1-metil-5-nitro-imidazolina e composizioni terapeutiche che li comprendono come principio attivo.
ES8305721A1 (es) Un procedimiento para la preparacion de derivados del pirbuterol.
MX9203234A (es) Derivados de 5-halovinil-2-desoxiuridina y composiciones farmaceuticas que los contienen.
AR002204A1 (es) Compuestos piridiniminil-1,2-bencisoxazoles y bencisotiazoles utiles como agentes para aliviar la disfuncion de la memoria, compuestos intermediarios,procedimientos de preparacion, composiciones que hacen uso de dichos compuestos e intermediarios.
MX9203068A (es) Compuestos activirales oralmente activos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 669919

Country of ref document: ES